[go: up one dir, main page]

FR2908892B1 - PROCESS FOR THE CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY AND NEED FOR CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY IN PLASMAS OR THERAPEUTIC FRACTIONS - Google Patents

PROCESS FOR THE CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY AND NEED FOR CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY IN PLASMAS OR THERAPEUTIC FRACTIONS

Info

Publication number
FR2908892B1
FR2908892B1 FR0610181A FR0610181A FR2908892B1 FR 2908892 B1 FR2908892 B1 FR 2908892B1 FR 0610181 A FR0610181 A FR 0610181A FR 0610181 A FR0610181 A FR 0610181A FR 2908892 B1 FR2908892 B1 FR 2908892B1
Authority
FR
France
Prior art keywords
activity
factor viii
chromogenic assay
plasmas
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0610181A
Other languages
French (fr)
Other versions
FR2908892A1 (en
Inventor
Jean Amiral
Anne Marie Vissac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyphen Biomed SAS
Original Assignee
Hyphen Biomed SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyphen Biomed SAS filed Critical Hyphen Biomed SAS
Priority to FR0610181A priority Critical patent/FR2908892B1/en
Publication of FR2908892A1 publication Critical patent/FR2908892A1/en
Application granted granted Critical
Publication of FR2908892B1 publication Critical patent/FR2908892B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4728Details alpha-Glycoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/90287Oxidoreductases (1.) oxidising metal ions (1.16)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR0610181A 2006-11-21 2006-11-21 PROCESS FOR THE CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY AND NEED FOR CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY IN PLASMAS OR THERAPEUTIC FRACTIONS Expired - Fee Related FR2908892B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0610181A FR2908892B1 (en) 2006-11-21 2006-11-21 PROCESS FOR THE CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY AND NEED FOR CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY IN PLASMAS OR THERAPEUTIC FRACTIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610181A FR2908892B1 (en) 2006-11-21 2006-11-21 PROCESS FOR THE CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY AND NEED FOR CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY IN PLASMAS OR THERAPEUTIC FRACTIONS

Publications (2)

Publication Number Publication Date
FR2908892A1 FR2908892A1 (en) 2008-05-23
FR2908892B1 true FR2908892B1 (en) 2009-02-20

Family

ID=38222712

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0610181A Expired - Fee Related FR2908892B1 (en) 2006-11-21 2006-11-21 PROCESS FOR THE CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY AND NEED FOR CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY IN PLASMAS OR THERAPEUTIC FRACTIONS

Country Status (1)

Country Link
FR (1) FR2908892B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102798598A (en) * 2011-05-25 2012-11-28 兆科药业(合肥)有限公司 Method for detecting enzymatic activity of phospholipid-depending factor X activator

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60186760A (en) * 1984-03-05 1985-09-24 Sekisui Chem Co Ltd Blood coagulation accelerator
CA2065370C (en) * 1990-07-12 2000-04-04 Hendrik Coenraad Hemker Factor viii:ca chromogenic assay
JPH08327631A (en) * 1995-06-01 1996-12-13 Eisai Co Ltd Reagent for measuring blood coagulation activity
DK0947585T3 (en) * 1998-03-19 2001-10-01 Instrumentation Lab Spa Improved in vitro method, kits and reagents for screening for blood clotting defects
NZ516400A (en) * 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions

Also Published As

Publication number Publication date
FR2908892A1 (en) 2008-05-23

Similar Documents

Publication Publication Date Title
FR15C0046I2 (en) DRUGS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
EP1838320A4 (en) ANTAGONISTS OF CXCR4 FOR THE TREATMENT OF MEDICAL DISORDERS
EP2099375A4 (en) METHODS AND DEVICES FOR MINIMAL INVASION FOR THE TREATMENT OF PROSTATE DISEASES
IL228952A0 (en) Medicinal preparations containing ferric-citrate for reducing the level of phosphate in the serum, and their use in the preparation of medicines for the treatment or relief of calcium-related disorders
EP1755598A4 (en) METHODS OF TREATING ARTHRITISES IN DOGS
EP1638950A4 (en) CYCLOHEXYLGLYCIN DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
NO20034388L (en) Therapeutic agent for chronic arthritis diseases in child-related diseases
EP1781303A4 (en) METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS
EP2497498A4 (en) THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES OR ALLERGY AND SCREENING METHOD FOR THE THERAPEUTIC AGENT
EP1793858A4 (en) ANTI-CTLA4 HUMAN MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER
EP1919480A4 (en) ANTAGONISTS OF THE HEDGEHOG PATH TO TREAT DISEASES
EP1865972A4 (en) TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS
ATE512948T1 (en) BIPHENYL-SULFONYL AND PHENYL-HETEROARYL-SULFONYL MODULATORS OF THE HISTAMINE H3 RECEPTOR FOR THE TREATMENT OF RELATED DISEASES
FR2900734B1 (en) DETECTION OF THROMBOEMBOLIC VENOUS DISEASES BY THE ASSAY OF D-DIMERS AND SOLUBLE FIBRIN
EP2341936A4 (en) METHODS FOR THE TREATMENT OR PREVENTION OF IL-1ß RELATED DISEASES
EP2069377A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND DISORDERS
FR2882654B1 (en) USE OF DIOSMETIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF THROMBOTIC DISEASES
FR2891163B1 (en) CATALYST FOR THE PREPARATION OF PENTAFLUOROETHANE AND THE PROCESS OF PREPARATION THEREOF
EP1830873A4 (en) GLYPONECTIN (ADIPONECTIN GLYCOSYLE) FOR THE TREATMENT OF DISEASES AND CONDITIONS
FR2919187B1 (en) USE OF YEAST SKIN FOR THE TREATMENT AND / OR PREVENTION OF HYPERINSULINEMIA.
PL1912513T3 (en) Novel milk protein fractions and use thereof for preventing or treating chronic inflammatory diseases
EP2331130A4 (en) IGE ANTIBODIES FOR THE TREATMENT OF CANCER
FR2903999B1 (en) MODULATORS OF SC4MOL IN THE TREATMENT OF ACNE OR HYPERSEBORRHEA
EP2126129A4 (en) APOPTOSIS-ASSOCIATED PROTEIN KINASE 1 (DAPK1) AND USES THEREOF FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
FR2908892B1 (en) PROCESS FOR THE CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY AND NEED FOR CHROMOGENIC ASSAY OF FACTOR VIII: C ACTIVITY IN PLASMAS OR THERAPEUTIC FRACTIONS

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

ST Notification of lapse

Effective date: 20220705